REVITALIZING THERAPEUTICS: DRUG REPURPOSING AS A COST-EFFECTIVE STRATEGY FOR DRUG DEVELOPMENT
DOI:
https://doi.org/10.22159/ijap.2024v16i3.49581Keywords:
Drug repurposing, Oncology, Anthelmintics, COVID-19, M. Tuberculosis and SildenafilAbstract
The process of developing new drugs is known for being drawn-out, expensive, risky, and having a high attrition rate. Drug repurposing has grown in favor recently as a practical way to speed up the development of new medicines while reducing the costs and time constraints associated with traditional drug research. The description of this study's pharmacological repurposing highlights its promise as a practical method to fill gaps in the market and revitalize treatment options. This review provides a full analysis of the ground-breaking tactic of repurposing medications, supported by numerous cases that demonstrate its revolutionary potential. We examine instances of repurposed drugs, such as thalidomide, sildenafil, and metformin, that have performed astoundingly well in a range of therapeutic settings despite being used outside of their original scope.
Overall, the paper's main goal-to study pharmacological repurposing as a potentially successful strategy for revitalizing treatments-is, succinctly summarized in this abstract. It highlights the potential benefits of this approach and how it might be used in the pharmaceutical industry's ongoing quest for more inexpensive and effective medicine development.
Downloads
References
Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Nov 22;3(8):673-83. doi: 10.1038/nrd1468, PMID 15286734.
Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012 Mar 1;11(3):191-200. doi: 10.1038/nrd3681, PMID 22378269.
Naylor S, Kauppi DM, Schonfeld JP. Therapeutic drug repurposing, repositioning and rescue part II: business review. Roundtable on translating genomic-based research for health; board on health sciences policy; Institute of Medicine. Drug repurposing and repositioning: workshop summary. Drug Discov World. Washington (DC): National Academies Press (US). 2014 Aug 8:16(2):57-72, PMID 24872991.
Chong CR, Sullivan DJ Jr. New uses for old drugs. Nature. 2007 Aug 9;448(7154):645-6. doi: 10.1038/448645a, PMID 17687303.
Cha Y, Erez T, Reynolds IJ, Kumar D, Ross J, Koytiger G. Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol. 2018 Jan;175(2):168-80. doi: 10.1111/bph.13798, PMID 28369768, PMCID PMC5758385.
Parveen S, Alnoman RB, Bayazeed AA, Alqahtani AM. Computational insights into the drug repurposing and synergism of FDA-approved influenza drugs binding with SARS-CoV-2 protease against COVID-19. Am J Microbiol Res. 2020;8(3):93-102.
Vaidya B, Parvathaneni V, Kulkarni NS, Shukla SK, Damon JK, Sarode A. Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer. Int J Biol Macromol. 2019 Feb 1;122:338-47. doi: 10.1016/j.ijbiomac.2018.10.181, PMID 30401652.
Kulkarni NS, Guererro Y, Gupta N, Muth A, Gupta V. Exploring potential of quantum dots as dual modality for cancer therapy and diagnosis. J Drug Deliv Sci Technol. 2019;49:352-64. doi: 10.1016/j.jddst.2018.12.010.
Kulkarni NS, Parvathaneni V, Shukla SK, Barasa L, Perron JC, Yoganathan S. Tyrosine kinase inhibitor conjugated quantum dots for non-small cell lung cancer (NSCLC) treatment. Eur J Pharm Sci. 2019 May 15;133:145-59. doi: 10.1016/j.ejps.2019.03.026, PMID 30946965.
Graul AI, Sorbera L, Pina P, Tell M, Cruces E, Rosa E. The year’s new drugs & biologics–2009. Drug News Perspect. 2010 Jan-Feb;23(1):7-36. doi: 10.1358/dnp.2010.23.1.1440373, PMID 20155217.
Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Nov 22;3(8):673-83. doi: 10.1038/nrd1468, PMID 15286734–683.
Krishnamurthy. Grimshaw N, AA, Axson SA, Choe SH, Miller JE. Drug repurposing: a systematic review on root causes, barriers and facilitators. BMC Health Serv Res. 2022;22(1):1-17.
Mignani S, Huber S, Tomás H, Rodrigues J, Majoral JP. Why and how have drug discovery strategies in pharma changed? What are the new mindsets? Drug Discov Today. 2016 Feb;21(2):239-49. doi: 10.1016/j.drudis.2015.09.007, PMID 26376356.
Novac N. Challenges and opportunities of drug repositioning. Trends Pharmacol Sci. 2013 May;34(5):267-72. doi: 10.1016/j.tips.2013.03.004, PMID 23582281.
Vanhaelen Q, Mamoshina P, Aliper AM, Artemov A, Lezhnina K, Ozerov I. Design of efficient computational workflows for in silico drug repurposing. Drug Discov Today. 2017 Feb;22(2):210-22. doi: 10.1016/j.drudis.2016.09.019, PMID 27693712.
Hatzimouratidis K. Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence. Clin Interv Aging. 2006;1(4):403-14. doi: 10.2147/ciia.2006.1.4.403, PMID 18046917, PMCID PMC2699643.
Hurle MR, Yang L, Xie Q, Rajpal DK, Sanseau P, Agarwal P. Computational drug repositioning: from data to therapeutics. Clin Pharmacol Ther. 2013 Apr;93(4):335-41. doi: 10.1038/clpt.2013.1, PMID 23443757.
Knight JM, Kerswill SA, Hari P, Cole SW, Logan BR, D’Souza A. Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. BMC Cancer. 2018;18(1):593. doi: 10.1186/s12885-018-4509-0, PMID 29793446.
Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Nov 22;3(8):673-83. doi: 10.1038/nrd1468, PMID 15286734.
S. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019 Jan;18(1):41-58. doi: 10.1038/nrd.2018.168, PMID 30310233.
Liu Z, Fang H, Reagan K, Xu X, Mendrick DL, Slikker W Jr. In silico drug repositioning: what we need to know. Drug Discov Today. 2013 Feb;18(3-4):110-5. doi: 10.1016/j.drudis.2012.08.005, PMID 22935104.
Scotti L, Mendonca Junior FJ, Ishiki HM, Ribeiro FF, Singla RK, Barbosa Filho JM. Docking studies for multi-target drugs. Curr Drug Targets. 2017;18(5):592-604. doi: 10.2174/1389450116666150825111818, PMID 26302806.
Challener Cynthia A. Can artificial intelligence take the next step for drug repositioning? PharmTech. 2018;42(9):22-6.
Laudisi F, Maronek M, Di Grazia A, Monteleone G, Stolfi C. Repositioning of anthelmintic drugs for the treatment of cancers of the digestive system. Int J Mol Sci. 2020 Jul 13;21(14):4957. doi: 10.3390/ijms21144957, PMID 32668817, PMCID PMC7404055.
Armando RG, Mengual Gomez DL, Gomez DE. New drugs are not enough drug repositioning in oncology: an update. Int J Oncol. 2020 Mar;56(3):651-84. doi: 10.3892/ijo.2020.4966. PMID 32124955, PMCID PMC7010222.
Guerini AE, Triggiani L, Maddalo M, Bonù ML, Frassine F, Baiguini A. Mebendazole as a candidate for drug repurposing in oncology: an extensive review of current literature. Cancers (Basel). 2019 Aug 31;11(9):1284. doi: 10.3390/cancers11091284, PMID 31480477, PMCID PMC6769799.
Russell DG. Mycobacterium tuberculosis and the intimate discourse of a chronic infection. Immunol Rev. 2011 Mar;240(1):252-68. doi: 10.1111/j.1600-065X.2010.00984.x, PMID 21349098, PMCID PMC3174472.
Kaur D, Mathew S, Nair CGS, Begum A, Jainanarayan AK, Sharma M. Structure-based drug discovery for designing leads for the non-toxic metabolic targets in multi-drug resistant Mycobacterium tuberculosis. J Transl Med. 2017 Dec 21;15(1):261. doi: 10.1186/s12967-017-1363-9, PMID 29268770, PMCID PMC5740895.
Konreddy AK, Rani GU, Lee K, Choi Y. Recent drug-repurposing-driven advances in the discovery of novel antibiotics. Curr Med Chem. 2019;26(28):5363-88. doi: 10.2174/0929867325666180706101404, PMID 29984648.
Naicker N, Sigal A, Naidoo K. Metformin as host-directed therapy for TB treatment: scoping review. Front Microbiol. 2020 Apr 29;11:435. doi: 10.3389/fmicb.2020.00435, PMID 32411100, PMCID PMC7201016.
Tiberi S, du Plessis N, Walzl G, Vjecha MJ, Rao M, Ntoumi F. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis. 2018 Jul;18(7):e183-98. doi: 10.1016/S1473-3099(18)30110-5. Erratum in: Lancet infect, Dis. 2018 Apr 27. PMID 29580819.
Mishra R, Krishan S, Siddiqui AN, Kapur P, Khayyam KU, Sharma M. Potential role of adjuvant drugs on efficacy of first-line oral antitubercular therapy: drug repurposing. Tuberculosis (Edinb). 2020 Jan;120:101902. doi: 10.1016/j.tube.2020.101902, PMID 32090863.
Miro Canturri A, Ayerbe Algaba R, Smani Y. Corrigendum: drug repurposing for the treatment of bacterial and fungal infections. Front Microbiol. 2022;13:844615. doi: 10.3389/fmicb.2022.844615, PMID 35283839.
Pacios O, Blasco L, Bleriot I, Fernandez Garcia L, Gonzalez Bardanca M, Ambroa A. Strategies to combat multidrug-resistant and persistent infectious diseases. Antibiotics (Basel). 2020 Feb 6;9(2):65. doi: 10.3390/antibiotics9020065, PMID 32041137, PMCID PMC7168131.
Coelho TS, Halicki PCB, Silva L Jr, de Menezes Vicenti JR, Gonçalves BL, Almeida da Silva PE. Metal-based antimicrobial strategies against intramacrophage mycobacterium tuberculosis. Lett Appl Microbiol. 2020 Aug;71(2):146-53. doi: 10.1111/lam.13298, PMID 32286695.
Battah B, Chemi G, Butini S, Campiani G, Brogi S, Delogu G. A repurposing approach for uncovering the anti-tubercular activity of FDA-approved drugs with potential multi-targeting profiles. Molecules. 2019 Nov 29;24(23):4373. doi: 10.3390/molecules24234373, PMID 31795400, PMCID PMC6930672.
Guerra-De-Blas PDC, Bobadilla-Del-Valle M, Sada Ovalle I, Estrada Garcia I, Torres Gonzalez P, Lopez Saavedra A. Simvastatin enhances the immune response against Mycobacterium tuberculosis. Front Microbiol. 2019 Sep 20;10:2097. doi: 10.3389/fmicb.2019.02097, PMID 31616387, PMCID PMC6764081.
Kim JH, O’Brien KM, Sharma R, Boshoff HIM, Rehren G, Chakraborty S. A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence. Proc Natl Acad Sci USA. 2013;110(47):19095-100. doi: 10.1073/pnas.1315860110, PMID 24191058.
Ranjbar S, Haridas V, Nambu A, Jasenosky LD, Sadhukhan S, Ebert TS. Cytoplasmic RNA sensor pathways and nitazoxanide broadly inhibit intracellular mycobacterium tuberculosis growth. iScience. 2019 Dec 20;22:299-313. doi: 10.1016/j.isci.2019.11.001, PMID 31805434, PMCID PMC6909047.
Torfs E, Piller T, Cos P, Cappoen D. Opportunities for overcoming Mycobacterium tuberculosis Drug resistance: emerging mycobacterial targets and host-directed therapy. Int J Mol Sci. 2019 Jun 12;20(12):2868. doi: 10.3390/ijms20122868, PMID 31212777, PMCID PMC6627145.
Botta L, Rivara M, Zuliani V, Radi M. Drug repurposing approaches to fight dengue virus infection and related diseases. Front Biosci (Landmark Ed). 2018 Jan 1;23(6):997-1019. doi: 10.2741/4630, PMID 28930586.
Bhakat S, Delang L, Kaptein S, Neyts J, Leyssen P, Jayaprakash V. Reaching beyond HIV/HCV: nelfinavir as a potential starting point for broad-spectrum protease inhibitors against dengue and Chikungunya virus. RSC Adv. 2015;5(104):85938-49. doi: 10.1039/C5RA14469H.
Eyer L, Valdes JJ, Gil VA, Nencka R, Hrebabecky H, Sala M. Nucleoside inhibitors of tick-borne encephalitis virus. Antimicrob Agents Chemother. 2015 Sep;59(9):5483-93. doi: 10.1128/AAC.00807-15, PMID 26124166, PMCID PMC4538560.
Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents. 2007 Oct;30(4):297-308. doi: 10.1016/j.ijantimicag.2007.05.015, PMID 17629679, PMCID PMC7126847.
Klumpp K, Leveque V, Le Pogam S, Ma H, Jiang WR, Kang H. The novel nucleoside analog R1479 (4’-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem. 2006;281(7):3793-9. doi: 10.1074/jbc.M510195200, PMID 16316989.
Nguyen NM, Tran CN, Phung LK, Duong KT, Huynh A, Farrar J. A randomized, double-blind placebo-controlled trial of Balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis. 2013 May 1;207(9):1442-50. doi: 10.1093/infdis/jis470, PMID 22807519, PMCID PMC3610419.
Boonyasuppayakorn S, Reichert ED, Manzano M, Nagarajan K, Padmanabhan R. Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity. Antiviral Res. 2014 Jun;106:125-34. doi: 10.1016/j.antiviral.2014.03.014, PMID 24680954, PMCID PMC4523242.
Durantel D. Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. Curr Opin Investig Drugs. 2009 Aug;10(8):860-70, PMID 19649930.
Whitby K, Taylor D, Patel D, Ahmed P, Tyms AS. Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C. Antivir Chem Chemother. 2004 May;15(3):141-51. doi: 10.1177/095632020401500304, PMID 15266896.
St John AL. Influence of mast cells on dengue protective immunity and immune pathology. PLOS Pathog. 2013;9(12):e1003783. doi: 10.1371/journal.ppat.1003783, PMID 24367254, PMCID PMC3868513.
Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R. Dasatinib in imatinib-resistant philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15;354(24):2531-41. doi: 10.1056/NEJMoa055229, PMID 16775234.
Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313, PMID 30207593.
Aggarwal S, Verma SS, Aggarwal S, Gupta SC. Drug repurposing for breast cancer therapy: old weapon for new battle. Semin Cancer Biol. 2021 Jan;68:8-20. doi: 10.1016/j.semcancer.2019.09.012, PMID 31550502, PMCID PMC7128772.
Royce ME, Osman D. Everolimus in the treatment of metastatic breast cancer. Breast Cancer (Auckl). 2015 Sep 6;9:73-9. doi: 10.4137/BCBCR.S29268, PMID 26417203, PMCID PMC4571987.
Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012 Feb 9;366(6):520-9. doi: 10.1056/NEJMoa1109653, PMID 22149876, PMCID PMC5705195.
Sykes MP, Karnofsky DA, Philips FS, Burchenal JH. Clinical studies on triethylenephosphoramide and diethylenephosphoramide, compounds with nitrogen-mustard‐like activity. Cancer. 1953;6(1):142-8. doi: 10.1002/1097-0142(195301)6:1<142::AID-CNCR2820060114>3.0.CO;2-W.
Kim KW, Roh JK, Wee HJ, Kim C. Cancer drug discovery, Springer; 2016.
Pawar AY. Combating devastating COVID-19 by drug repurposing. Int J Antimicrob Agents. 2020 Aug;56(2):105984. doi: 10.1016/j.ijantimicag.2020.105984, PMID 32305589, PMCID PMC7162749.
Dotolo S, Marabotti A, Facchiano A, Tagliaferri R. A review on drug repurposing applicable to COVID-19. Brief Bioinform. 2021 Mar 22;22(2):726-41. doi: 10.1093/bib/bbaa288, PMID 33147623, PMCID PMC7665348.
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W. Addendum: a pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;588(7836):E6. doi: 10.1038/s41586-020-2951-z, PMID 33199918.
Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929-36. doi: 10.1056/NEJMoa2001191, PMID 32004427.
Nicastri E, Petrosillo N, Ascoli Bartoli T, Lepore L, Mondi A, Palmieri F. National institute for the infectious diseases ”L. Spallanzani”, IRCCS. Recommendations for COVID-19 clinical management. Infect Dis Rep. 2020 Mar 16;12(1):8543. doi: 10.4081/idr.2020.8543, PMID 32218915, PMCID PMC7097833.
Ortega JT, Serrano ML, Pujol FH, Rangel HR. Unrevealing sequence and structural features of novel coronavirus using in silico approaches: the main protease as molecular target. Excli J. 2020 Mar 17;19:400-9. doi: 10.17179/excli2020-1189, PMID 32210741, PMCID PMC7081067.
Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020 Feb 17;35(6):e79. doi: 10.3346/jkms.2020.35.e79, PMID 32056407, PMCID PMC7025910.
Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S. [Management of COVID-19: the Zhejiang experience. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 Feb 21;49(2):147-57. doi: 10.3785/j.issn.1008-9292.2020.02.02, PMID 32391658, PMCID PMC8800711.
Jyothi BJ, Kavya VR. “Ultraviolet spectrophotometric method development for estimation of new antiviral repurposing drug favipiravir. Asian J Pharm Clin Res. 2021;14(7 Jul):67-9. doi: 10.22159/ajpcr.2021.
Choudhary DG, K Kumar J. A study to assess knowledge, attitude and practice on breast cancer among women in government general hospital. Asian Journal of Pharmaceutical and Clinical Research. 2021;14(2):60-5. doi: 10.22159/ajpcr.2021.v14i2.40244.
Published
How to Cite
Issue
Section
Copyright (c) 2024 SHIVANI MAKHIJANI
This work is licensed under a Creative Commons Attribution 4.0 International License.
